CME
Podcast
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
This Oncology PER®Spectives™ podcast examines the recent advancements in the treatment landscape for advanced melanoma. In this activity, experts Yana Najjar, MD; Rahul A. Sheth, MD, FSIR; and Douglas Johnson, MD, MSCI, discuss the challenges of immune checkpoint inhibitor resistance and the practical strategies for overcoming this by using direct intratumoral injections of oncolytic viral immunotherapies, which rely on close interdisciplinary collaboration between medical oncologists and interventional radiologists.
Target Audience
This educational activity is directed toward a primary target audience of interventional radiologists and a secondary target audience of medical oncologists, nurse practitioners, physician assistants, and nurses who treat patients with advanced melanoma.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Replimune Group, Inc.
Faculty:
Yana Najjar, MD
Associate Professor of Medicine
Director, Clinical and Translational Research Center
UPMC Hillman Cancer Center
Pittsburgh, PA
Disclosures: Speakers’ Bureau: Immunocore, Pfizer; Adviser: Bristol Myers Squibb, Immunocore, Merck, Novartis, Pfizer, Replimune, Therakos
Douglas B. Johnson, MD, MSCI
Co-Leader, Translational Research and Interventional Oncology Research Program
Professor of Medicine (Hematology/Oncology)
Clinical Director, Melanoma Vanderbilt-Ingram Medical Center
Nashville, TN
Disclosures: Consultant: Jackson Labs, Teiko; Advisory Board: AstraZeneca, Bristol Myers Squibb, Merck, Pfizer
Rahul A. Sheth, MD, FSIR
Associate Professor, Department of Interventional Radiology, Division of Diagnostic Imaging
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Boston Scientific; Consultant: Boston Scientific, Inari Medical, Johnson & Johnson, Medtronic, NanOlogy, Replimune, TriSalus Life Sciences
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Release Date
June 5, 2025
Expiration Date
June 5, 2026